Sarepta Therapeutics
SRPT
$118.59
Share price
-2.17%
Change (1 day)
23.39%
Change (1 year)
Categories
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.
Revenue for Sarepta Therapeutics (SRPT)
Revenue in 2023 (TTM): $1.00 B
According to Sarepta Therapeutics 's latest financial reports the company's current revenue (TTM) is $1.00 B. In 2022 the company made a revenue of $0.93 B an increase over the years 2021 revenue that were of $0.70 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sarepta Therapeutics from 2001 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $1.00 B | 7.55% |
| 2022 | $0.93 B | 32.93% |
| 2021 | $0.70 B | 29.96% |
| 2020 | $0.54 B | 41.82% |
| 2019 | $0.38 B | 26.51% |
| 2018 | $0.30 B | 94.74% |
| 2017 | $0.15 B | 2751.58% |
| 2016 | $5.42 M | 332.64% |
| 2015 | $1.25 M | -87.16% |
| 2014 | $9.75 M | -31.38% |
| 2013 | $14.21 M | -61.91% |
| 2012 | $37.32 M | -20.56% |
| 2011 | $46.99 M | 59.72% |
| 2010 | $29.42 M | 67.31% |
| 2009 | $17.58 M | -17.28% |
| 2008 | $21.25 M | 93.52% |
| 2007 | $10.98 M | 9428.23% |
| 2006 | $0.11 M | -97.59% |
| 2005 | $4.78 M | 1011.31% |
| 2004 | $0.43 M | -55.62% |
| 2003 | $0.96 M | 15.9% |
| 2002 | $0.83 M | 18.51% |
| 2001 | $0.7 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | $27.38 B | 2,628.83% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $0.81 B | -18.41% | 🇺🇸 USA |
 Novavax NVAX | $1.44 B | 43.55% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $1.23 B | 23.32% | 🇺🇸 USA |
 Insmed INSM | $0.26 B | -73.14% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | $0.30 B | -69.44% | 🇺🇸 USA |
 Avidity Biosciences RNA | $9.8 M | -99.02% | 🇺🇸 USA |